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Poly(ethylene carbonate) (PEC) is an unique biomaterial showing significant potential 
for controlled drug delivery applications. The current study investigated the impact of the 
molecular weight on the biological performance of drug-loaded PEC films. 
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Following the preparation and thorough physicochemical characterization of diverse 
PEC (molecular weights: 85, 110, 133, 174 and 196 kDa), the degradation and drug release 
behavior of rifampicin- and bovine serum albumin-loaded PEC films was investigated in vitro 
(in the presence and absence of cholesterol esterase), in cell culture (RAW264.7 macrophages) 
and in vivo (subcutaneous implantation in rats). All investigated samples degraded by means 
of surface erosion (mass loss, constant molecular weight), which was accompanied by a 
predictable, eroding-controlled drug release pattern. Accordingly, the obtained in vitro 
degradation half-lives correlated well with the observed in vitro half-times of drug delivery 
(R2 = 0.96). Here, the PEC of the highest molecular weight resulted in the fastest 
degradation/drug release. When incubated with macrophages or implanted in animals, the 
degradation rate of PEC films superimposed the results of in vitro incubations with cholesterol 
esterase. Interestingly, SEM analysis indicated a distinct surface erosion process for enzyme-, 
macrophage- and in vivo-treated polymer films in a molecular weight-dependent manner. 
Overall, the molecular weight of surface-eroding PEC was identified as an essential 
parameter to control the spatial and temporal on-demand degradation and drug release from 
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BSA  bovine serum albumin 
Ð  dispersity 
DSC  differential scanning calorimetry 
[η]  intrinsic viscosity 
ηsp  specific viscosity 
FITC  fluoresceine isothiocyanate 
GPC  gel permeation chromatography 
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Mw  weight-average molecular weight 
PBS  phosphate-buffered saline 
PEC  poly(ethylene carbonate) 
SD  standard deviation 
SEM  scanning electron microscopy 
t1/2  half-time/half-life 
Tg  glass transition temperature 
wt.%  weight percent 





Advances in the field of chemical engineering and the biomedical sciences have made 
polymer drug carriers available, which allow for modification of the delivery rate of the 
embedded therapeutic agent [1]. The drug release may occur constantly over an extended 
period of time, typically by means of polymer degradation and/or diffusion through the 
polymer matrix, with the aim of obtaining constant plasma levels, reducing side effects and 
prolonging dosing intervals [2]. Biodegradable polyesters such as poly(lactide-co-glycolide) 
have been most-frequently utilized as matrix materials for controlled drug delivery devices [3, 
4]. However, the hydrolytic degradation behavior (i.e., bulk erosion [5], formation of acidic 
microclimate within the drug carrier [6]) often results in a rather uncontrolled drug release 
profile [7] and chemical instability for numerous therapeutic agents [8, 9]. 
In contrast, polymers that degrade solely by surface erosion have demonstrated more 
predictable drug release kinetics [10]. Biodegradable poly(ethylene carbonate) (PEC) is a 
promising example of such polymer [11]. Diverse PEC-based drug delivery vehicles have been 
shown to degrade from the surface in vitro and in vivo [11-13], resulting in a favorable drug 
release profile [14, 15]. Furthermore, the degradation of PEC is triggered by specific enzymes 
and cells [16, 17] making this type of polymer especially attractive for on-demand drug release 
to desired sites within the body [18]. Despite the significant potential of PEC for controlled 
drug delivery applications, only scant information is available describing the biomedical 
performance (i.e., biodegradation and drug release) of drug delivery vehicles composed of PEC 
of different molecular weight [19]. 
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In this respect, the current study aimed to close this gap by investigating the impact of 
the polymer molecular weight on the degradation of and drug release rate from surface-eroding 
PEC films in detail. Polymers and polymer films either loaded with rifampicin or fluorescently-
labelled bovine serum albumin (BSA) were thoroughly characterized before studying their in 
vitro degradation and drug release behavior in the absence and presence of the enzyme 
cholesterol esterase. Degradation tests in cell culture (i.e., RAW264.7 macrophages) and in 
vivo (i.e., subcutaneous implantation in rats) underlined the unique potential of PEC for 
prolonged drug delivery applications. 
 
 
2 MATERIALS AND METHODS 
 
2.1 Materials. PEC, QPAC®25 was purchased from Empower Materials (USA). PEC 
polymers of lower molecular weight were obtained by thermal hydrolysis in boiling water 
(Figure S1, Supplementary materials) [16, 17, 19]. rifampicin (≥97 %), fluorescein 
isothiocyanate (FITC)-labeled BSA (≥7 mol FITC/mol BSA) and cholesterol esterase (from 
porcine pancreas) were acquired from Sigma-Aldrich (UK). All other chemicals and solvents 
were of analytical grade and used without further purification. 
 
2.2 Gel permeation chromatography (GPC). Samples were dissolved in chloroform 
(3-4 mg/ml). After filtration (0.2 µm; Acrodisc®, Pall, Germany), 100 µl of the sample solution 
was injected into the system, consisting of two columns from Polymer Laboratories (PL-gel 
MIXED-D; 300×7.5 mm; bead diameter 5 µm) and a differential refractive index detector 
(SpectraSystem RI-150, Thermo Electron Corp., USA). The elution was performed with 
chloroform at a flow rate of 1 ml/min and toluene as flow-rate marker. Poly(methyl 
methacrylate) standards of known molar masses were used for calibration. 
 
2.3 Viscosity measurements. The viscosity of PEC samples dissolved in chloroform 
was measured using a capillary viscometer of the Ubbelohde Semi-Micro dilution type (No. 
50, N213, CANNON Instrument Company, USA) at 25.0 ± 0.2 °C. Values for the specific (ηsp) 
and intrinsic viscosity ([η]) were calculated using standard equations. 
 
2.4 Differential scanning calorimetry (DSC). The glass transition temperature (Tg) of 
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polymers and polymer films was determined using a differential scanning calorimeter 
(Discovery DSC, TA Instruments, Denmark). Samples (~3-5 mg) were scanned at a rate of 10 
°C/min from -40 °C to 190 °C under a nitrogen atmosphere. 
 
2.5 X-ray powder diffraction (XRPD). Wide-angle XRPD patterns were recorded on 
a X’Pert PROMPD X-ray diffractometer (PANalytical, The Netherlands). Samples were 
measured in Bragg Brentano reflection mode in the 2θ range of 5 - 37 using a PIXel detector 
(step size of 0.039). The X-ray source was Ni-filtered CuKα1 radiation (λ = 1.541 Å). The 
operating current and voltage were 40 mA and 45 kV, respectively. The aluminum sample 
holder was spun throughout data collection to avoid orientation artifacts. 
 
2.6 Scanning electron microscopy (SEM). Samples were placed on double-sided 
carbon tape, mounted on stubs and sputter coated with a 5 nm layer of gold using a Leica EM 
ACE200 (Germany) prior to sample imaging. The images were acquired with an FEI/Philips 
XL30 FEG (USA) at an acceleration voltage of 2 kV using the secondary electron detector. 
 
2.7 Preparation of polymer films. PEC films were fabricated by a solvent casting 
technique [20, 21]. Therefore, PEC without or with added rifampicin (10 wt.% per polymer 
mass) were accurately weighed and then dissolved in chloroform at a concentration of 100 
mg/ml. For films loaded with BSA, PEC was first dissolved in chloroform (100 mg/ml) 
containing Span® 80 (1 mg/ml). BSA was dissolved in water (10 mg/ml) in parallel before 
mixing the two solutions (ratio of 9/1 (v/v)) using a homogenizer (T25 Ultra-Turrax®, IKA, 
Germany). Film solutions (500 µl) were then transferred to custom-made Teflon® dishes 
(diameter: 10 mm, height: 3 mm) and the organic solvent was allowed to evaporate under a 
fume hood overnight. The films were then cut into discs, and dried under reduced pressure 
(~0.1 mbar). 
 
2.8 Enzymatic polymer degradation. Polymer film samples (~25 mg) were 
transferred to 2 ml of phosphate-buffered saline (PBS, pH 7.4) without or with added 
cholesterol esterase (0.1 mg/ml). The films were incubated at 37 °C with shaking (Rotatherm®, 
Gebr. Liebisch, Germany). The medium was exchanged every 3-4 d. At predetermined time 
points the incubation was terminated by removal of the supernatant. Polymer films were 
washed several times with distilled water and subsequently freeze-dried (Beta I, Christ, 
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Germany) overnight. The remaining film mass and molecular weight was determined 
gravimetrically (BP 211 D, Sartorius, Germany) and by GPC as described above, respectively. 
 
2.9 Drug release from polymer films. The in vitro drug release studies were carried 
out in PBS without or with added cholesterol esterase (0.1 mg/ml) under sink conditions. 
~30 mg of rifampicin-loaded (drug loading of 10 wt.%) or BSA-loaded (drug loading of 1 
wt.%) PEC films were incubated in the release medium while shaking at 37 °C. The release 
medium was removed at each sampling time point and replaced with fresh medium before 
determining the cumulative drug release. 
 
2.10 Rifampicin quantification. Rifampicin concentrations were assessed by 
reversed-phase high performance liquid chromatography on a Shimadzu system (Japan) using 
a Phenomenex Kinetex XB-C18 (50 mm × 2.1 mm, 2.6 μm) column (Denmark) (flow rate of 
0.5 ml/min). Samples were analyzed using a 5-15 % (v/v) B gradient over 3.5 min with the 
mobile phases composed of solvent A (95/5 MeCN/H2O + 0.1 % TFA (v/v)) and solvent B 
(5/95 MeCN/H2O + 0.1 % TFA (v/v)). Rifampicin was detected at a wavelength of 369 nm. 
 
2.11 BSA quantification. BSA concentrations were determined by fluorescence 
spectroscopy (FLUOstar OPTIMA, BMG labtech, Germany) and the bicinchoninic acid 
protein assay reagent (Pierce, USA). Fluorescence intensity (λex = 460 nm and λem = 515 nm) 
was assayed in 96-well microplates. The cumulative amount of BSA released was then 
calculated as described above. 
 
2.12 Cell culture. Murine macrophages (RAW264.7) were acquired from ATCC (TIP-
71, USA). Cells were maintained in Dulbecco’s Modified Eagle’s Medium supplemented with 
penicillin (100 U/ml), streptomycin (100 µg/ml), 2 mM L-glutamine (all from Sigma-Aldrich, 
UK) and 10 % (v/v) of fetal bovine serum (PAA Laboratories, Austria) and cultured in an air 
atmosphere conditioned with 5 % CO2 at 37°C. The medium was changed three times per week 
and cells were split twice weekly (cell detachment by scraping). Cells were used between 
passages 5 and 12. 
 
2.13 Cellular polymer degradation. PEC films (~50 mg) were disinfected with 
ethanol before transferring them into prefilled (50,000 macrophages per ml medium, 2.5 ml) 
6-well cell culture plates. The culture plates were then incubated as outlined above. At 
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predetermined time points, the incubation was stopped by removing the films from the well 
plates. The films were treated with 1 wt.% aqueous Triton X-100 detergent (Sigma-Aldrich, 
UK) for 60 min and then extensively rinsed with distilled water. After freeze-drying, the 
remaining film mass and molecular weight was determined as outlined above. 
 
2.14 Polymer degradation in vivo. Male Sprague-Dawley rats (~250 g; Charles River, 
Denmark) were used for the in vivo evaluation of polymer degradation. Animals were allowed 
free access to water and food and were housed under controlled environmental conditions 
(constant temperature and humidity with a 12 h dark-light cycle). 
The animals were anaesthetized by isoflurane/oxygen inhalation (Scanvet, Denmark) 
and kept with the mask during the entire surgical procedure. Buprenorphine (0.3 ml, 10 % in 
isotonic saline) was administered subcutaneously preoperatively. For each rat, the skin was 
incised along the midline of the back and two pockets were prepared by dissecting the 
subcutaneous tissue on both right and left side of the incision. Into each pocket, one polymer 
film of 1 cm2 (thickness of 1-2 mm) of predetermined molecular weight (around 60 mg in 
total) was placed followed by skin closure. Following 3, 7 and 10 d, animals were 
anaesthetized and the films were retrieved, cleaned and freeze-dried for weighing and 
molecular weight determination. Animals were finally euthanized by an overdose of sodium 
pentobarbital. 
All experiments and procedures described herein were in accordance with the National 
Institutes of Health guidelines on the care and use of laboratory animals. The study protocol 
was further approved by the Danish Animal Experiments Inspectorate (approval no. 2014-
15-0201-00031). 
 
2.15 Statistics. All experiments/measurements were carried out in triplicate and values 
are presented as the mean ± standard deviation (SD) unless otherwise stated. To identify 
statistically significant differences, an unpaired t-test analysis was performed. Probability 
values of p <0.05 were considered significant. 
 
 
3 RESULTS & DISCUSSION 
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The medical field would clearly profit from polymer excipients allowing for a 
predictable drug release behavior. Further, it would be attractive to design drug delivery 
vehicles with certain specificity for cells and/or tissues and thus, an on-demand release in order 
to minimize systemic drug distribution [18]. This task is often difficult to achieve, especially 
when employing bulk-eroding polymers such as poly(lactide-co-glycolide) [5, 7, 22]. In 
contrast, surface-eroding PEC comprises significant potential to meet these specific 
requirements. However, as the speed of biodegradation dictates the release kinetics of the 
encapsulated therapeutic agent for drug delivery devices undergoing surface erosion, a deeper 
understanding of the influence of the molecular weight of the utilized PEC is therefore, 
considered important. 
 
3.1 Characterization of polymers and drug-loaded polymer films. The 
physicochemical properties of the synthesized PEC are outlined in Table 1. Polymers with 
different weight-average molecular weight (Mw) were prepared by thermal hydrolysis of 
commercially available PEC196 (Figure S1, Supplementary materials) [16, 17, 19] with the 
aim to study the impact of Mw on the biomedical performance of polymer films in detail. The 
Mw of degraded polymer samples, assessed by means of GPC, ranged between 196 and 85 kDa. 
GPC analysis further indicated relatively broad dispersities (Ð) of degraded polymers (>2.0) 
[12], which were, however, more narrowly distributed than the starting material (PEC196) 
(Figures S1B and S2, Supplementary materials). The approach of Ð towards 2 is an indication 
of random chain scission during the employed degradation process. Proton nuclear magnetic 
resonance spectroscopy confirmed the composition (>95 % ethylene glycol) of the utilized 
polymers (data not shown). 
 
[insert Table 1 here] 
 
The viscosity of the polymers dissolved in chloroform increased as a function of the 
polymer concentration and Mw (Figure S3, Supplementary Materials). [η] values ranged 
between 0.6 and 1.0 dl/g (Table 1). The relationship of [η] and Mw of PEC dissolved in 
chloroform is illustrated in Figure S4 (Supplementary Materials), which showed a linear 
correlation for the investigated polymers. Application of the Mark-Houwink equation for the 
specific polymer-solvent system, gave a value of 0.032 dl/g and 0.66 for k and α, respectively. 
The exponent α is indicative of the PEC chain geometry in chloroform. A value of 0.5 indicates 
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a θ-solvent, while a value between 0.5 and 0.8 reflects a random polymer coil in a “good” 
solvent. 
DSC measurements of the distinct polymers showed minor differences in Tg, with all 
polymers having a Tg below room temperature (Table 1). The Tg of PEC85 (15 °C) was the 
lowest, while that of PEC196 was the highest (17 °C). Elevated Tg values are typically seen 
when increasing the Mw of amorphous and semi-crystalline polymers (Flory-Fox relationship) 
[23]. It was further observed, that Rifampicin-loaded PEC films (10 wt.%) showed a higher Tg 
compared to the polymers alone. Thus, rifampicin shifted the drug-polymer mixture toward 
higher Tg, most-likely due to an anti-plasticizer effect of this drug [24, 25]. For all rifampicin-
loaded PEC films a single Tg event was observed (data not shown), which is an indication of 
the drug being molecularly dispersed in the polymer matrix. In contrast, embedded BSA had 
no relevant influence on the Tg of the investigated PEC films. 
XRPD was performed for the PEC polymers and rifampicin-loaded PEC films (10 
wt.%) (Figure 1). All polymers (Figure 1A) and rifampicin-loaded polymer samples 
(Figure 1B) were amorphous, while unprocessed rifampicin powder alone was crystalline. This 
result supports the thermoanalytical measurements, where all samples showed no melting 
endotherm for rifampicin. BSA-loaded PEC films were also of amorphous nature (data not 
shown). 
 
[insert Figure 1 here] 
 
3.2 Polymer film degradation. Degradation studies of the PEC films were performed 
in the presence and absence of cholesterol esterase (Figure 2). This enzyme is expressed by 
several cells including macrophages [26] and pancreatic cells [27] and has been demonstrated 
to actively degrade PEC in vitro [16]. Polymer films showed clear signs of surface erosion in 
the presence of cholesterol esterase (no degradation in PBS without added cholesterol esterase). 
Interestingly, the degradation rate was shown to be dependent on the Mw of the employed 
polymer (Figure 2A). 
 
[insert Figure 2 here] 
 
Faster degradation was observed for higher Mw (PEC196, degradation half-life (t1/2) of 
~9 d), whereas PEC85 revealed remarkably slower degradation rates (degradation t1/2 of ~14 
d). Figure 2B illustrates that the polymer Mw remained constant throughout the degradation 
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study under both incubation conditions. Thus, the length of individual polymer chains remained 
constant while the film samples experienced relevant mass loss, indicating erosion of a full-
length polymer chain from the film. 
This behavior is strikingly different from what is typically reported for bulk-eroding 
polymers. As an example, poly(lactide-co-glycolide) undergoes a mass loss and decrease in 
polymer Mw once in contact with aqueous media [22]. Shorter polymer chains (lower Mw) 
generally tend to experience a quicker degradation process compared with longer polymer 
chains (higher Mw). One possible explanation for the observed degradation rates for PEC films 
of different Mw could be attributed to differences in the individual polymer structure. As 
outlined by Acemoglu et al. [12], the synthesis of PEC results in the formation of both -
(O(CO)OCH2CH2)- and -(O(CO)(OCH2CH2)x)- repeating units. Here, the -
(O(CO)(OCH2CH2)x)- units, which are thought to be selectively hydrolyzed during the aqueous 
thermal degradation process used to generate the lower Mw specimens of PEC, are more 
hydrophilic. Thus, PEC196 is expected to be the most hydrophilic polymer of the series. 
Accordingly, the polymer degradation by cholesterol esterase (and the accompanied rapid drug 
release profiles) showed an “inverse” dependency on Mw. This hypothesis was challenged by 
incubating PEC196 and PEC85 with cholesterol esterase and comparing the morphology of the 
degraded films by means of SEM (Figure 3). As expected, a rough surface with pore formation 
was visible for PEC196 films indicating a relieved degradation by cholesterol esterase of this 
polymer. In contrast, the surface of PEC85 films was rather “smooth” over the time-course of 
incubation (only little difference was seen to freshly-prepared PEC films (Figure S5, 
Supplementary materials)). In this context, the polymer chain flexibility needs to be 
considered, where PEC196 is thought to relax (“healing” process of polymer surface) the 
slowest because of the higher Mw [28]. Thus, the surface of PEC85 remained “smoother” 
during enzyme degradation, due to less pronounced erosion and a higher rate for “repair” of 
the surface. 
 
[insert Figure 3 here] 
 
3.3 Drug release. The release of a small, rather hydrophobic drug and a large, 
hydrophilic protein was studied from the diverse PEC films (Figures 4-6). In the absence of 
cholesterol esterase, no relevant burst release of rifampicin (<10 %) was detected, indicating 
no relevant diffusional drug transport through the polymer matrix (Figure 4A). 
 
	 11 
[insert Figure 4 here] 
 
In contrast, a gradual rifampicin release from all investigated polymer films was 
obtained in the presence of cholesterol esterase, however, at substantial different release rates 
(Figure 4B). Here, PEC196 showed the fastest drug release rate followed by PEC174, PEC133, 
PEC110 and PEC85. PEC196 released ~75 % of its payload over 14 d, while PEC85 delivered 
only ~40 % of the encapsulated rifampicin content. 
The calculated t1/2 values of PEC film degradation (Figure 2) and rifampicin release 
curves (Figure 4) in the presence of cholesterol esterase were plotted, where a linear correlation 
was obtained (Figure 5). 
 
[insert Figure 5 here] 
 
The slope of the resulting line of regression was >1, which is indicative for a slightly 
faster rifampicin release compared to what one would expect by a drug release process 
mediated by “simple” surface erosion. 
In a second set of release experiments, the delivery of BSA was studied from PEC films 
in the absence and presence of cholesterol esterase (Figure 6). Without added cholesterol 
esterase, PEC196 experienced a considerably higher BSA release (~30-40 %) compared to 
PEC85 (<10 %) (Figure 6A). 
 
[insert Figure 6 here] 
 
When incubated with cholesterol esterase, a progressive BSA release was seen from 
the investigated PEC196 and PEC85 films, again at substantial different release rates (Figure 
6B). PEC196 delivered the complete BSA payload within the incubation period. In contrast, 
PEC85 showed a slower BSA release profile with ~60 % of the encapsulated amount delivered 
after 14 d. As discussed above (Figures 2 and 3), this elevated BSA release rate observed for 
PEC196 is likely attributed to the difference in polymer degradation by cholesterol esterase, 
leading to a distinct drug release profile [15, 16, 19]. 
Overall, the release of rifampicin and BSA from PEC films of different Mw matched 
the observations made during the film degradation study, where the highest polymer erosion 
rate was seen for the PEC with the highest Mw (i.e., PEC196). Thus, the Mw-dependent erosion 
of PEC could be used to tailor a desired release profile for both rather small drugs and 
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biomacromolecules. Here, especially rifampicin revealed remarkably linear (predictable) 
release kinetics. It was further demonstrated in vitro, that the drug delivery from PEC was 
initiated by an enzyme-specific surface erosion process of the delivery vehicle, which can be 
considered as a prerequisite for an on-demand drug delivery to a desired cell population or 
tissue/organ within the body. Bulk-eroding polymers, such as conventional polyesters, share 
none of these auspicious features [5, 22, 29]. 
 
3.4 Polymer film degradation by macrophages and in vivo. Degradation studies in 
cell culture and in vivo underlined the unique potential of PEC as biomaterial for prolonged 
drug delivery applications (Figures 7-10). Polymer films, which were incubated with 
RAW264.7 macrophages, showed rapid mass loss as a function of the employed Mw with 
degradation t1/2 of ~3 and ~5 d for PEC196 and PEC85, respectively (Figure 7A). During the 
incubation process, no relevant change of polymer Mw was detected (Figure 7B). 
 
[insert Figure 7 here] 
 
No degradation occurred in plain cell culture medium (i.e., no mass loss, change of 
polymer Mw or film surface (data not shown)), while the morphology of the freshly-prepared 
PEC films (Figure S5, Supplementary materials) changed dramatically when incubated with 
macrophages (Figure 8). As it can be seen from the SEM images, the surface of degraded 
PEC196 and PEC85 films revealed obvious difference with respect to the porous 
microstructure. PEC196 films showed mainly numerous small pores (with a cross-section <10 
µm) as well as large holes (cross section >200 m), where the macrophages had fully 
penetrated the polymer film. In contrast, degraded PEC85 films were characterized by an 
overall lower number of pores. Besides bigger holes, which matched the size of RAW264.7 
macrophages (10-20 µm in diameter), also smaller pores below the size of the cells were 
visible. These findings further indicated that the polymer structure of PEC196 films was easier 
to penetrate for the RAW264.7 macrophage cell line. 
 
[insert Figure 8 here] 
 
Thus, the process by which the polymer films were degraded by RAW264.7 
macrophages (i.e., surface erosion) was in general agreement with the observations from the 
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studies with cholesterol esterase (Figures 2 and 3). However, the overall rate of PEC 
degradation was more pronounced in cell culture (Figure 7). One possible explanation for the 
distinct extent of surface erosion could be the higher local concentration of distinct degrading 
enzymes (and/or radicals) of RAW264.7 macrophages, which are found in close proximity to 
the polymer film, compared to “simple” cholesterol esterase solution. 
Degradation studies of polymer films were also performed after subcutaneous 
implantation in rats (Figures 9 and 10). PEC196 and PEC85 films were rapidly eroded in vivo 
(Figure 9A), with no significant change of Mw over the time-course of implantation 
(Figure 9B). The mechanism (i.e., surface erosion) and overall rate of polymer degradation in 
vivo were similar to the studies conducted with cholesterol esterase (Figure 2) and RAW264.7 
macrophages (Figure 7). 
 
[insert Figure 9 here] 
 
When comparing the time-course of PEC196 and PEC85 film morphology during in 
vivo degradation (Figure 10), the surface structure of PEC196 and PEC85 and thus, the specific 
surface erosion mechanism by which the two tested polymers were degraded, was strikingly 
different. As seen for cholesterol esterase-mediated (Figure 3) and RAW264.7 macrophage-
mediated (Figure 8) polymer film degradation, numerous pores were formed on the surface of 
PEC196, which then transformed to a ”rough” polymer interface with time. 
 
[insert Figure 10 here] 
 
In contrast, the surface of PEC85 films was rather “smooth”, characterized by less, but 
larger scoop-like pores, which underwent significant progression during the time-course of in 
vivo degradation. Previous studies have reported that the biodegradation of PEC in vivo was 
mainly triggered by immuno-competent cells, which rapidly attached to the polymer surface 
after implantation [11, 14]. Released enzymes (and/or radicals) then initiated the surface 
degradation process. Here, a close proximity of macrophages to the PEC surface was 
considered essential [14]. However, these general findings cannot explain the observed 
discrepancy of surface morphology for PEC196 and PEC85 films during in vitro and in vivo 
degradation and its general implication on an accompanied drug release process. Besides the 
faster rate of surface erosion observed for PEC196, the formation of many ”small” pores and a 
”rough” film surface during biodegradation (increase in surface area) would cause an even 
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A biomaterial with potential for an on-demand drug release would add significant 
benefit to the biomedical field. Controlled drug delivery vehicles, which could defer drug 
release until reaching a certain target and/or are “activated” by specific stimuli (e.g., enzymes 
or cells) would limit systemic drug exposure and drug dose, and consequently reduce side 
effects. Among the large number of natural and synthetic polymers, PEC is one of such 
promising biomaterials, which undergoes enzyme- and cell-specific surface erosion in vitro 
and in vivo. Consequently, delivery systems made from PEC result in predictable drug release 
patterns. In this respect, the current study identified the molecular weight of PEC as an essential 
parameter to control the spatial and temporal drug release from the employed delivery system. 
Overall, surface-eroding PEC is thought to result in a suitable on-demand drug release to the 
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Figure 1. XRPD patterns of PEC polymers (A), rifampicin powder and rifampicin-loaded PEC 
films (B). 
 
Figure 2. Degradation kinetics (remaining film mass (A) and remaining polymer Mw (B)) of 
PEC films in the absence (open symbols) and presence (filled symbols) of cholesterol esterase. 
No SD bars are shown, if the SD fell into the symbol. The asterisks denote statistically 
significant difference compared to PEC85. For an interpretation of the color code, readers are 
referred to Figure 1. 
 
Figure 3. SEM images of PEC films incubated with cholesterol esterase for 5 d. 
 
Figure 4. In vitro drug release profiles from rifampicin-loaded PEC films in the absence (A) 
and presence (B) of cholesterol esterase. No SD bars are shown, if the SD fell into the symbol. 
The asterisks denote statistically significant difference compared to PEC85. For an 
interpretation of the color code, readers are referred to Figure 1. 
 
Figure 5. Correlation of polymer degradation of (Figure 2) and drug release from (Figure 4) 
rifampicin-loaded PEC films. The straight line represents a linear fit of the experimental data 
(R2 = 0.96). For an interpretation of the color code, readers are referred to Figure 1. 
 
Figure 6. In vitro protein release profiles from BSA-loaded PEC films in the absence (A) and 
presence (B) of cholesterol esterase. No SD bars are shown, if the SD fell into the symbol. The 
asterisks denote statistically significant difference compared to PEC85. For an interpretation 
of the color code, readers are referred to Figure 1. 
 
Figure 7. Degradation kinetics (remaining film mass (A) and remaining polymer Mw (B)) of 
PEC films incubated with RAW264.7 macrophages. No SD bars are shown, if the SD fell into 
	 19 
the symbol. The asterisks denote statistically significant difference compared to PEC85. For 
an interpretation of the color code, readers are referred to Figure 1. 
 
Figure 8. SEM images of PEC196 and PEC85 films incubated with RAW264.7 macrophages 
for 5 d. Scale bars = 100 µm. 
 
Figure 9. Degradation kinetics (remaining film mass (A) and remaining polymer Mw (B)) of 
PEC films implanted in rats. Values are presented as the mean ± SD (n ≥ 6). No SD bars are 
shown, if the SD fell into the symbol. The asterisks denote statistically significant difference 
compared to PEC85. For an interpretation of the color code, readers are referred to Figure 1. 
 
Figure 10. SEM images of the time-course of PEC196 and PEC85 film degradation after 
implantation in rats. Scale bars = 100 µm. 
 






















